Literature DB >> 1287675

Dose-response relationships with antihypertensive drugs.

G D Johnston1.   

Abstract

A variety of antihypertensive drugs have been introduced into clinical practice at excessively high dose. Examples include most thiazide diuretics, propranolol, oxprenolol, atenolol, methyldopa, hydralazine and captopril. These very high doses have usually resulted from studies in which doses have been increased at regular intervals until the desired antihypertensive effect has been achieved or until unacceptable adverse effects have resulted. Frequently the starting doses were too high and the intervals between dose adjustment too short. In many cases these large doses resulted in unnecessary adverse effects--the adverse biochemical effects of thiazide diuretics, nephrotic syndrome, taste disturbances and neutropenia with captopril, the lupus syndrome with hydralazine and the central nervous system effects of methyldopa. Parallel group design with single doses and sufficient statistical power to distinguish between the upper and lower ends of the antihypertensive dose-response relationship should replace the dose-escalating design.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287675     DOI: 10.1016/0163-7258(92)90029-y

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  7 in total

Review 1.  The implications of noncompliance with antihypertensive medication.

Authors:  B Girvin; G D Johnston
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

2.  Predicted impact of various clinical practice strategies on cardiovascular risk for the treatment of hypertension: a clinical trial simulation study.

Authors:  Yuyan Jin; Robert Bies; Marc R Gastonguay; Yaning Wang; Norman Stockbridge; Jogarao Gobburu; Rajanikanth Madabushi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-18       Impact factor: 2.745

3.  Intravenous hydralazine for blood pressure management in the hospitalized patient: its use is often unjustified.

Authors:  Patrick Campbell; William L Baker; Stephen D Bendel; William B White
Journal:  J Am Soc Hypertens       Date:  2011-09-03

4.  Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new "physiologically based" model to assess absorption and disposition.

Authors:  Yanfeng Wang; Zhijun Wang; Zhong Zuo; Brian Tomlinson; Benjamin T K Lee; Michael B Bolger; Moses S S Chow
Journal:  AAPS J       Date:  2013-04-19       Impact factor: 4.009

Review 5.  Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.

Authors:  Jessica C Song; C Michael White
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 5.577

6.  Hydralazine target: from blood vessels to the epigenome.

Authors:  Claudia Arce; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Myrna Candelaria; Alfonso Dueñnas-Gonzalez
Journal:  J Transl Med       Date:  2006-02-28       Impact factor: 5.531

Review 7.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.